0001209191-23-013450.txt : 20230227 0001209191-23-013450.hdr.sgml : 20230227 20230227201542 ACCESSION NUMBER: 0001209191-23-013450 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230225 FILED AS OF DATE: 20230227 DATE AS OF CHANGE: 20230227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chen Hubert C CENTRAL INDEX KEY: 0001622297 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38052 FILM NUMBER: 23677776 MAIL ADDRESS: STREET 1: C/O PFENEX INC. STREET 2: 10790 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Forte Biosciences, Inc. CENTRAL INDEX KEY: 0001419041 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261243872 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3060 PEGASUS PARK DRIVE STREET 2: BUILDING 6 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (310) 618-6994 MAIL ADDRESS: STREET 1: 3060 PEGASUS PARK DRIVE STREET 2: BUILDING 6 CITY: DALLAS STATE: TX ZIP: 75247 FORMER COMPANY: FORMER CONFORMED NAME: Tocagen Inc DATE OF NAME CHANGE: 20071120 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-25 0 0001419041 Forte Biosciences, Inc. FBRX 0001622297 Chen Hubert C C/O FORTE BIOSCIENCES, INC. 3060 PEGASUS PARK DR., BLDG 6 DALLAS TX 75247 0 1 0 0 See remarks Restricted Stock Units 2023-02-25 4 A 0 120000 0.00 A Common Stock 120000 120000 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. President and Chief Scientific Officer /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact 2023-02-27